Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves Read more
Knight Therapeutics Inc. places No. 90 on The Globe and Mail’s fifth-annual ranking of Canada’s Top Growing Companies Read more
US FTC suspends challenge to block Amgen’s $27.8 billion deal for Horizon Therapeutics By Reuters Read more